Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity

JAMA Network Open, Journal Year: 2022, Volume and Issue: 5(9), P. e2231982 - e2231982

Published: Sept. 19, 2022

Importance No retrospective cohort study has assessed the effectiveness of semaglutide at doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg). Objective To weight loss outcomes associated with treatment for patients overweight or obesity. Design, Setting, Participants This study, conducted a referral center management, retrospectively collected data on use adults between January 1, 2021, March 15, 2022, follow-up up 6 months. A total 408 body mass index (BMI) 27 more were prescribed weekly subcutaneous injections 3 months more. Patients history bariatric procedures, taking other antiobesity medications, an active malignant neoplasm excluded. Exposures Weekly 1.7-mg 2.4-mg Main Outcomes Measures The primary end point was percentage loss. Secondary points proportion achieving 5% more, 10% 15% 20% after without type 2 diabetes Results included 175 (132 women [75.4%]; mean [SD] age, 49.3 [12.5] years; BMI, 41.3 [9.1]) analysis 102 (SD) 6.7 (4.4) kg, equivalent 5.9% (3.7%) ( P < .001), 12.3 (6.6) 10.9% (5.8%) .001 from baseline). Of who followed months, 89 (87.3%) achieved 56 (54.9%) 24 (23.5%) 8 (7.8%) had lower compared those diabetes: 3.9% (3.1%) vs 6.3% = .001) 7.2% (6.3%) 11.8% (5.3%) .005). Conclusions Relevance results this suggest that similar seen trials. Studies longer periods are needed evaluate prolonged outcomes.

Language: Английский

---

Ten things to know about ten cardiovascular disease risk factors – 2022

American Journal of Preventive Cardiology, Journal Year: 2022, Volume and Issue: 10, P. 100342 - 100342

Published: April 6, 2022

The American Society for Preventive Cardiology (ASPC) "Ten things to know about ten cardiovascular disease risk factors - 2022" is a summary document regarding (CVD) factors. This 2022 update provides tables of 10 CVD and builds upon the foundation prior annual versions factors" published since 2020. version perspective ASPC members includes updated sentinel references (i.e., applicable guidelines select reviews) each factor section. include unhealthful dietary intake, physical inactivity, dyslipidemia, pre-diabetes/diabetes, high blood pressure, obesity, considerations populations (older age, race/ethnicity, sex differences), thrombosis (with smoking as potential contributor thrombosis), kidney dysfunction genetics/familial hypercholesterolemia. Other may be relevant, beyond discussed here. However, it intent provide tabular overview most common preventive cardiology ready access reviews.

Language: Английский

---

Changing the global obesity narrative to recognize and reduce weight stigma: A position statement from the World Obesity Federation

Obesity Reviews, Journal Year: 2023, Volume and Issue: 25(1)

Published: Oct. 17, 2023

Summary Weight stigma, defined as pervasive misconceptions and stereotypes associated with higher body weight, is both a social determinant of health human rights issue. It imperative to consider how weight stigma may be impeding promotion efforts on global scale. The World Obesity Federation (WOF) convened working group practitioners, researchers, policymakers, youth advocates, individuals lived experience obesity the ways that narratives contribute stigma. Specifically, focused overall narratives, food physical activity scientific public‐facing language impact across lifespan was also considered. Taking perspective, nine recommendations resulted from this work for research can help reduce harmful inside outside contexts.

Language: Английский

---

Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024

Journal of clinical lipidology, Journal Year: 2024, Volume and Issue: 18(3), P. e320 - e350

Published: April 24, 2024

BACKGROUNDThis joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk.METHODSThis is based upon scientific evidence, perspectives authors, peer OMA NLA leadership.RESULTSAmong individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles.CONCLUSIONSObesity increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. Among patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD. This risk. leadership. particles.

Language: Английский

---

Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024

Obesity Pillars, Journal Year: 2024, Volume and Issue: 10, P. 100108 - 100108

Published: March 12, 2024

This joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk. is based upon scientific evidence, perspectives authors, peer OMA NLA leadership. Among individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles. increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD.

Language: Английский

---

Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021

The Lancet, Journal Year: 2025, Volume and Issue: 405(10481), P. 813 - 838

Published: March 1, 2025

Overweight and obesity is a global epidemic. Forecasting future trajectories of the epidemic crucial for providing an evidence base policy change. In this study, we examine historical trends global, regional, national prevalence adult overweight from 1990 to 2021 forecast 2050. Leveraging established methodology Global Burden Diseases, Injuries, Risk Factors Study, estimated among individuals aged 25 years older by age sex 204 countries territories Retrospective current were derived based on both self-reported measured anthropometric data extracted 1350 unique sources, which include survey microdata reports, as well published literature. Specific adjustment was applied correct self-report bias. Spatiotemporal Gaussian process regression models used synthesise data, leveraging spatial temporal correlation in epidemiological trends, optimise comparability results across time geographies. To generate estimates, forecasts Socio-demographic Index patterns presented annualised rate change inform trajectories. We considered reference scenario assuming continuation trends. Rates increased at regional levels, all nations, between 2021. 2021, 1·00 billion (95% uncertainty interval [UI] 0·989-1·01) males 1·11 (1·10-1·12) females had obesity. China largest population adults with (402 million [397-407] individuals), followed India (180 [167-194]) USA (172 [169-174]). The highest age-standardised observed Oceania north Africa Middle East, many these reporting more than 80% adults. Compared 1990, 155·1% (149·8-160·3) 104·9% UI 100·9-108·8) females. most rapid rise East super-region, where rates tripled doubled. Assuming 2050, that total number living will reach 3·80 3·39-4·04), over half likely time. While China, India, continue constitute large proportion obesity, sub-Saharan super-region forecasted increase 254·8% (234·4-269·5). Nigeria specifically, 141 (121-162) making it country fourth-largest No date has successfully curbed rising Without immediate effective intervention, globally. Particularly Asia Africa, driven growing populations, substantially. These regions face considerable obesity-related disease burden. Merely acknowledging health issue would be negligent part public practitioners; aggressive targeted measures are required address crisis, one foremost avertible risks now poses unparalleled threat premature death local, national, levels. Bill & Melinda Gates Foundation.

Language: Английский

---

Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023

Obesity Pillars, Journal Year: 2023, Volume and Issue: 5, P. 100056 - 100056

Published: Jan. 28, 2023

This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of type 2 diabetes mellitus (T2DM), obesity-related cardiometabolic risk factor.

Language: Английский

---

Weight loss efficiency and safety of tirzepatide: A Systematic review

PLoS ONE, Journal Year: 2023, Volume and Issue: 18(5), P. e0285197 - e0285197

Published: May 4, 2023

Objective Tirzeptide is a novel glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drug, which shows good efficiency for weight loss. Therefore, we aim to investigate the efficacy safety of tirzepatide loss in type 2 diabetes mellitus (T2DM) obesity patients this meta-analysis study. Methods Cochrane Library, PubMed, Embase, Clinical Trials, Web Science were searched from inception October 5, 2022. All randomized controlled trials (RCTs) included. The odds ratio (OR) was calculated using fixed-effects or random-effects models by Review Manager 5.3 software. Results In total, ten studies (12 reports) involving 9,873 identified. A significant body group versus placebo -9.81 kg (95% CI (-12.09, -7.52), GLP-1 RAs -1.05 (-1.48, -0.63), insulin -1.93 (-2.81, -1.05), respectively. sub-analysis, significantly reduced three doses (5 mg, 10 15 mg) when compared with those placebo/GLP-1 RA/insulin. terms safety, incidence any adverse events leading study drug discontinuation higher group, but serious hypoglycaemia lower. Additionally, gastrointestinal (including diarrhea, nausea, vomiting decreased appetite) than placebo/basal insulin, similar RAs. Conclusion conclusion, tirzeptide can reduce T2DM patient obesity, it potential therapeutic regimen weight-loss, need be vigilant about its reaction.

Language: Английский

---

Cancer and Obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022

Obesity Pillars, Journal Year: 2022, Volume and Issue: 3, P. 100026 - 100026

Published: July 5, 2022

Language: Английский

---

Obesity and hypertension: Obesity medicine association (OMA) clinical practice statement (CPS) 2023

Obesity Pillars, Journal Year: 2023, Volume and Issue: 8, P. 100083 - 100083

Published: Aug. 7, 2023

This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) provides an overview of the mechanisms and treatment obesity hypertension.

Language: Английский

---